Drugs News and Research

RSS

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology.

19 Jun 2014

Medicare faces cost tension with lawmakers, advocates

More than 130 lawmakers are urging the Obama administration to expand coverage for a lung-cancer test under Medicare that could cost the program billons, calling the screening important for vulnerable seniors. In a letter to the Centers for Medicare and Medicaid Services, the lawmakers called for a timely decision on coverage for low-dose CT scans for older patients at higher risk of developing lung cancer. ... A CMS spokesman said the agency's decision will be based on whether the test is "reasonable and necessary," without regard to its cost to Medicare (Yen, 6/17).

19 Jun 2014

Depression 5 times common in people with bipolar disorder who have low levels of cortisol

Depression is almost twice as common, and poor quality of life almost five times as common, in people with bipolar disorder who have elevated or low levels of the stress hormone cortisol in the blood.

19 Jun 2014

Generic drug delays cost U.S. payers millions

Problems surrounding an Indian company's launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal.

19 Jun 2014

Drug therapy for ADHD does not entail increased risk of suicide attempts

A new register-based study from Karolinska Institutet in Sweden shows that drug therapy for ADHD does not entail an increased risk of suicide attempts or suicide, as was previously feared. The results are published in the British Medical Journal (BMJ).

19 Jun 2014

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.

18 Jun 2014

First Edition: June 18, 2014

Today's headlines include a report that the cost of health law subsidies may push the measure's overall price tag beyond projections.

18 Jun 2014

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.

18 Jun 2014

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies.

18 Jun 2014

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

18 Jun 2014

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

18 Jun 2014

Brain iron levels offer potential biomarker in the diagnosis of ADHD

Brain iron levels offer a potential biomarker in the diagnosis of attention deficit hyperactivity disorder (ADHD) and may help physicians and parents make better informed treatment decisions, according to new research published online in the journal Radiology.

18 Jun 2014

New approach promises better drugs for diabetes and osteoporosis

By swapping replacement parts into the backbone of a synthetic hormone, UW-Madison graduate student Ross Cheloha and his mentor, Sam Gellman, along with collaborators at Harvard Medical School, have built a version of a parathyroid hormone that resists degradation in laboratory mice.

18 Jun 2014

New breakthrough in pediatric leukaemia treatment

Melbourne researchers have shown a type of leukaemia can be successfully 'reversed' by coaxing the cancer cells back into normal development.

18 Jun 2014

Researchers explore shiatsu to help people with chronic pain fall asleep

There was a time, back in Nancy Cheyne's youth, when she combined the poise and grace of a ballerina with the daring and grit of a barrel racer. When she wasn't pursuing either of those pastimes, she bred sheepdogs, often spending hours on her feet grooming her furry friends at dog shows.

18 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Academy of Nutrition and Dietetics applauds AMA's support for multidisciplinary obesity treatment

The Academy of Nutrition and Dietetics applauds the American Medical Association's recent decision to support increased patient access to evidence-based, multidisciplinary obesity treatment.

18 Jun 2014

New clinical guidelines on diagnosis and management of idiosyncratic DILI

New clinical guidelines on the diagnosis and management of idiosyncratic drug-induced liver injury (DILI) appear in the July issue of The American Journal of Gastroenterology.

18 Jun 2014

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.

18 Jun 2014

Drugs News and Research

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

Medicare faces cost tension with lawmakers, advocates

Depression 5 times common in people with bipolar disorder who have low levels of cortisol

Generic drug delays cost U.S. payers millions

Drug therapy for ADHD does not entail increased risk of suicide attempts

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

First Edition: June 18, 2014

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Brain iron levels offer potential biomarker in the diagnosis of ADHD

New approach promises better drugs for diabetes and osteoporosis

New breakthrough in pediatric leukaemia treatment

Researchers explore shiatsu to help people with chronic pain fall asleep

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Academy of Nutrition and Dietetics applauds AMA's support for multidisciplinary obesity treatment

New clinical guidelines on diagnosis and management of idiosyncratic DILI

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News